STIM1 and glioblastoma: Alternative splicing represents an economic mechanism to expand and diversify the function of signaling proteins.[26] Meanwhile, emerging data suggest that aberrant splicing promotes tumor growth and thus can be exploited for the development of novel cancer biomarkers.[27] In this study, we identified an alternatively spliced variant of STIM1, STIM1β, that is evolutionarily conserved among mammals but aberrantly upregulated in certain types of cancer, such as glioblastoma.